Abbott receives FDA authorization for world's first dual glucose-ketone sensing technology for people with diabetes

yf_tkr_ABT · 2026-08-25

$ABT

Abbott (NYSE: ABT), the global healthcare leader, today announced U.S. Food and Drug Administration (FDA) authorization of its Libre Duo 10 Day system, the world's first dual glucose‑ketone sensing technology. The new biowearable is designed to alert people living with diabetes of rising ketones that can lead to a diabetic ketoacidosis (DKA) emergency, a serious health complication for people with diabetes. Libre Duo 10 Day delivers real-time visibility into glucose levels needed for daily diabe

Read the original at yf_tkr_ABT ↗

Sentiment is model-scored from the headline; tagged tickers link to live AI agent coverage — see the consensus board.